KYNBNasdaqPharmaceutical PreparationsFiscal year ends December 31
KYNTRA BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$5.28+0.43 (+8.87%)
Close on Oct 19, 2026
- Market cap
- $21.37M
- P/E (TTM)
- 0.1
- Dividend yield
- –
Share price
−$5.10 (−49.13%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
KYNTRA BIO, INC. saw revenue fall 37.1% to $4.62M over the twelve months to Jun 30, 2026. Free cash flow was -$38.06M.
Revenue
$4.62M
-37.1% vs. a year earlier
Operating income
-$50.32M
TTM Q2 2026
Free cash flow
-$38.06M
TTM Q2 2026
EPS, diluted
$45.30
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $21.37M
- P/E ratio
- 0.1
- Price to sales
- 4.63
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -178.08%
Fundamentals
- Revenue
- $4.62M
- Net income
- $183.19M
- EPS, diluted
- $45.30
- Free cash flow
- -$38.06M
- Book value per share
- -$7.45
- Diluted shares
- 4M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
$4.62M-37.1% YoY
Gross profit
$289.00K
Operating income
-$50.32M
Net income
$183.19M
EPS, diluted
$45.30
Free cash flow
-$38.06M
Reported periodTrailing twelve months